The association of the CYP19 and CYP17 polymorphic markers with sporadic breast cancer

Molekulyarnaya Biologiya

Volumn 37, Issue 6, 2003, Pages 975-982

  Artamonov, V V ^a   Lyubchenko, L N ^b   Shabanov, M A ^b   Babenko, O V ^c   Nemtsova, M V ^a   Zaletaev, D V ^a,c  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CYTOCHROME P450 17; STEROID 17ALPHA MONOOXYGENASE;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; ENZYMOLOGY; GENETIC MARKER; GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ALLELES; AROMATASE; BREAST NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC MARKERS; HUMANS; POLYMORPHISM, GENETIC; SEQUENCE DELETION; STEROID 17-ALPHA-HYDROXYLASE;

EID: 2142640525     PISSN: 00268984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Claus E.B., Risch N., Thompson W.D. 1991. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 48, 232-242.
2. Ford D., Easton D.F. 1995. The genetics of breast and ovarian cancer. Br. J. Cancer. 72, 805-812.
3. Dunning A.M., Healey C.S., Pharoah P.D.P., Teare M.D., Ponder B.A.J., Easton D.F. 1999. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 8, 843-854.
4. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. 1993. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol. Rev. 15, 17-35.
5. Henderson B.E., Bernstein L. 1996. Endogenous and exogenous hormone factors. In: Harris J.R. (ed), Diseases and the Breast. Philidelphia, PA: Lippincott-Raven, 185-200.
6. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., Strax P., Pastenack B.A. 1995. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87, 190-197.
7. O'Neill J.S., Elton R.A., Miller W.R. 1988. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br. Med. J. 296, 741-743.
8. Bulun S.E., Price T.M., Mahendroo M.S., Aitken J., Simpson E.R. 1993. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77, 1622-1628.
9. Bulun S.E., Simpson E.R. 1999. Regulation of the CYP19 (P450arom) gene expression in breast adipose tissue and breast cancer. Trends Endocrinol. Metab. 10, 9-13.
10. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. 1993. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15, 17-35.
11. Brentano S.T., Picado-Leonard J., Mellon S.H., Moore C.C., Miller W.L. 1990. Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol. Endocrinol. 4, 1972-1979.
12. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., Franks S., Williamson R. 1994. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet. 3, 1873-1876.
13. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Stanczyk F.Z., Henderson B.E. 1998. Cytochrome P450cl7 gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58, 585-587.
14. Haiman C.A., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Speizer F.E., Kelsey K.T., Hunter D.J. 1999. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 59, 1015-1020.
15. Feigelson H.S., McKean-Cowdin R., Coetzee G.A., Stram D.O., Kolonel L.N., Henderson B.E. 2001. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 61, 785-789.
16. Kristensen V.N., Haraldsen E.K., Anderson K.B., Lonning P.E., Erikstein B., Karesen R., Gabrielsen O.S., Borresen-Dale A.-L. 1999. CYP17 and breast cancer risk: the polymorphism in the 5′-flanking area of the gene does not influence binding to Sp-1. Cancer Res. 59, 2825-2828.
17. Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. 1997. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57, 1063-1065.
18. Dunning A.M., Healey C.S., Pharoah P.D., Foster N.A., Lipscombe J.M., Redman K.L., Easton D.F., Day N.E., Ponder B.A. 1998. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br. J. Cancer. 77, 2045-2047.
19. Huang C.-S., Chern H.-D., Chang K.-J., Cheng C.-W., Hsu S.-M., Shen C.-Y. 1999. Breast cancer risk associated with genotype polymorphisms of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59, 4870-4875.
20. Thompson E.A., Jr., Siiteri P.K. 1974. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249, 5364-5372.
21. Grodin J.M., Siiteri P.K., MacDonald P.C. 1973. Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab. 38, 207-214.
22. Bulun S.E., Simpson E.R. 1994. Competitive reverse transcription- polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J. Clin. Endocrinol. Metab. 78, 428-432.
23. Siegelmann-Danieli N., Buetow K.H. 1999. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk. Br. J. Cancer. 79, 456-463.
24. Baxter S.W., Choong D.Y.H., Eccles D.M., Campbell I.G. 2001. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis. 22, 347-349.
25. Haiman C.A., Hankinson S.E., Speigelman D., De Vivo I., Colditz G.A., Willett W.C., Speizer F.E., Hunter D.J. 2000. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer. 87, 204-210.
26. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. 1998. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics. 8, 43-48.
27. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. 2000. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int. J. Cancer. 89, 325-328.
28. Healey C.S., Dunning A.M., Durocher F., Teare D., Pharoah P.D., Luben R.N., Easton D.F., Ponder B.A. 2000. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis. 21, 189-193.
29. 7 allele in premenopausal vs. postmenopausal breast cancer patients, but not in control individuals. Eur. J. Cancer. 38, 1911-1916.
30. Sambrook J., Fritsh E.F., Maniatis T. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, N.Y.: Cold Spring Harbor.
31. Haiman C.A, Brown M., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Kantoff P.C., Hunter D.J. 2002. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 62, 1045-1049.